Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
SAN JOSE, Calif. - Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $21.47 million, has announced a research collaboration with Tokyo-based Chugai Pharmaceutical Co., Ltd. The partnership, formalized on August 13, 2024, is aimed at evaluating the potential of Rani’s proprietary RaniPill® technology for delivering Chugai’s therapeutic antibodies. According to InvestingPro analysis, while the company’s stock is trading near its Fair Value, it faces significant financial challenges with an EBITDA of -$46.55 million in the last twelve months.
The RaniPill® capsule is designed to replace injections and infusions with an oral dosage form. In recent studies, the RaniPill® has shown comparable bioavailability to traditional subcutaneous delivery methods for two undisclosed molecules. This development could represent a significant shift in the administration of biologic drugs, which are typically delivered via injection or infusion due to their large molecule size and sensitivity to digestive enzymes. Despite the promising technology, InvestingPro data reveals the company generated only $1.2 million in revenue over the last twelve months, highlighting the early-stage nature of its operations.
Rani Therapeutics has a history of exploring various molecules with its RaniPill® technology, having preclinically evaluated 19 diverse molecules and completed three Phase 1 clinical trials. The company’s CEO, Talat Imran, expressed enthusiasm for the collaboration with Chugai, citing the Japanese firm’s innovative drug discovery technologies and the potential alignment with Rani’s oral delivery expertise.
Chugai Pharmaceutical, known for its proprietary antibody engineering technologies, also expressed optimism about the partnership. Tom Igawa, PhD, Head of Research at Chugai, highlighted Rani’s innovative approach as a promising avenue for enhancing the value of multiple drug development programs.
The announcement is based on a press release statement and reflects the ongoing efforts by both companies to innovate in drug delivery technologies. While the collaboration is still in the research phase, it underscores the industry’s interest in improving patient experiences and outcomes by simplifying the administration of biologic therapies.
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies for oral drug delivery. Chugai Pharmaceutical is a research-based pharmaceutical company with a strong presence in the Roche Group, aiming to address unmet medical needs with innovative products. Both companies have cautioned that forward-looking statements are subject to risks and uncertainties and that actual results may differ materially from those projected.
In other recent news, Rani Therapeutics Holdings reported its financial results for the fourth quarter of 2024, showing a net loss of $56.6 million, an improvement from the $67.9 million loss in 2023. The company introduced its first contract revenue of $1 million in 2024, while research and development expenses decreased significantly by $12.9 million. Rani Therapeutics faces potential delisting from the Nasdaq Stock Exchange due to non-compliance with the minimum market value of $50 million, with a deadline to regain compliance by October 28, 2025. Meanwhile, Oppenheimer adjusted its price target for Rani Therapeutics to $4.00 from $14.00, maintaining an Outperform rating. Stifel analysts also reiterated their Buy rating with an $8.00 price target, emphasizing the promising preclinical results of the RT-114 drug candidate. BTIG maintained a Buy rating with a $14.00 target, citing the potential of RT-114 in the obesity treatment market. Rani Therapeutics is set to advance its RT-114 drug into a Phase 1 clinical trial by mid-2025, focusing on its development as an oral treatment for obesity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.